A phase I dose ranging study of the safety, tolerability and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 trigene [V 520] and the MRKAd6 HIV-1 trigene [V 526] vaccines alone and in combination in healthy adults.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2014
At a glance
- Drugs V 520 (Primary) ; V 526 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms COMPLETED
- Sponsors Merck & Co
- 26 Feb 2009 Status changed from not stated to active, no longer recruiting.
- 24 Feb 2009 New source identified and integrated (ClinicalTrials.gov); planned end date is 1 Mar 2011.
- 20 Mar 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History